Last reviewed · How we verify
infusion of NMDA antagonist — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
infusion of NMDA antagonist (infusion of NMDA antagonist) — New York State Psychiatric Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| infusion of NMDA antagonist TARGET | infusion of NMDA antagonist | New York State Psychiatric Institute | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- infusion of NMDA antagonist CI watch — RSS
- infusion of NMDA antagonist CI watch — Atom
- infusion of NMDA antagonist CI watch — JSON
- infusion of NMDA antagonist alone — RSS
Cite this brief
Drug Landscape (2026). infusion of NMDA antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/infusion-of-nmda-antagonist. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab